To investigate whether the Tan Ⅱ A could improve the distribution and anti-tumor efficacy of Pegylated Liposomal Doxorubicin (PLD) via normalizing the structure and function of vasculature in Hepa1-6 hepatoma mice model.
INTRODUCTION
It is generally accepted that the growth and metastasis of solid tumors are dependent on angiogenesis. 1, 2 In 1971, Folkman 3 suggested a hypothesis that "starve" a tumor to death, that is, anti-angiogenesis was an effective way to avoid cancer. Over the past years, these finding have yielded very significant results, which have brought numbers of anti-angiogenic agents into pre-clinically or clinical trials. 4 However, these agents do not have any significant effect in patients with cancer when used alone. The comprehensive treatment that is combined therapy of anti-angiogenesis with chemotherapy and radiotherapy often produces a synergistic effect. [5] [6] [7] Then the mechanism underlying anti-angiogenic agents' action in these patients became the scope of research. Tumor angiogenesis is not simply the increased in the number of blood vessels. Firstly, tumor vessels are unordered, tortuous and saccular. 8, 9 The structure of the ves-sel wall is likewise abnormal, there are large gaps between endothelial cells, pericytes are detached and basement membranes are thickened or attenuated. 10, 11 The abnormal vascular structure leads to heterogeneous blood perfusion in tumor. 12 and further leads to abnormal tumor microenvironment, such as hypoxia, 13 decreased extracellular Ph, 14 increased interstitial fluid pressure (IFP), 15, 16 limited access of blood-borne drugs, and less effect of immune cells on tumor. 17, 18 Regarding these problems, Jain 19 proposed that appropriate anti-angiogenic agents could transiently normalize the abnormal structure and function of tumor vasculature by improving microenvironment and drug delivery. Certainly, some improvements has been made towards the mechanism of "vascular normalization", which involves inhibition of tumor vascular growth factor pathways (epidermal growth factor receptor [EGFR] and vascular endothelial growth factor receptor[VEG-FR]). [20] [21] [22] and modification of matrix metalloproteinases (MMPs), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2). 23 In theory, any therapy may induce normalization of tumor vasculature as long as it can restore the balance between pro-and anti-angiogenic molecules. 24, 25 Tan Ⅱ A is an active constituent of Salvia Miltiorrhiza Bunge with a clear chemical structure. In Traditional Chinese Medicine, Tan ⅡA is commonly used for cardiovascular disease, diabetes and cerebrovascular diseases. 26, 27 Moreover, recent studies have revealed that Tan Ⅱ A has marked anti-tumor effect. [28] [29] [30] A vast number of experiments have been carried out to study the anti-tumor mechanism. Tan Ⅱ A has proved effective in anti-angiogenesis both in vivo and in vitro. 31 On the one hand, Tan Ⅱ A could modulate the secretion of MMP-2 and TIMP-2 and decrease MMP-2 activities in vascular endothelial cells. 32 On the other hand, Tan Ⅱ A could down regulate the expression of cyclooxygenase-2 (COX-2) and hypoxia-inducible factor 1 (HIF-1α) to inhibit angiogenesis and increase the sensitivity of breast cancer cells to chemotherapy. 33 What is more, Tan ⅡA inhibits angiogenesis by down regulating the VEGF/ VEGFR2 pathway. 22 Therefore Tan Ⅱ A may play the role of anti-tumor by promoting blood vessel normalization. However, there is little evidence to support this hypothesis to date. We aimed to identify the effect of Tan Ⅱ A on tumor vasculature and hypoxia, as well as the probable synergistic anti-tumor effect when combined with PLD.
METHODS

Ethics approval
Animal care and experimental protocols were approved by the Sichuan Medical Experimental Animal Care Commission.
Cell lines, animal tumor model, and drug
Hepa1-6 Hepatoma cell line (Chinese Academy of Sciences) was cultured in RPMI-1640 medium containing 10% fetal bovine serum (Hyclone, Logan, UT, USA) and 1% penicillin/streptomycin (Hyclone, Logan, UT, USA) and kept in 37 ℃ in 5% CO2. Female, C57/BL/6J mice of 5-6 weeks of age and weighing approximately 20 g were purchased from the Laboratory Animal Center of Sichuan University (Chengdu, China). Hepa1-6 Hepatoma xenograft model was established by subcutaneous injection of 2 × 10 6 Hepa1-6 cells into the left armpit of the mice. Tan Ⅱ A (Sulfotanshinone Sodium Injection, 5 mg/ mL), were purchased from the first Biochemical Pharmaceutical Co., Ltd., Shanghai, China. Avastin (Bevacizumab injection, BV), commercially available from Roche Pharma (Shanghai) Ltd., Shanghai, China. PLD (pegylated piposomal doxorubicin injection, 10 mg/ mL), were purchased from Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co., Ltd., Shanghai, China.
Histology and immunohistochemistry (IHC)
When tumor volume reached approximately 200 mm 3 , mice were randomly allocated to three groups (n = 8 in each group), and received daily intraperitoneal injection NS, Tan ⅡA (5 mg·kg
) for 14 d, respectively. Animals were sacrificed by cervical dislocation for tumor tissue at 14 d after injection of the drugs. The tumors were fixed in 4% paraformaldehyde and embedded in paraffin. Then, adjacent sections with 3-5 µm thicknesses were cut from each tumor, mounted on glass slides and stained with hematoxylin and eosin. For immunohistochemistry, the endothelial cells were stained by rat anti-mouse CD31 monoclonal antibody (1∶100, BD Biosciences， San Diego, CA, USA), the pericytes were indentified with rabbit anti-moue α-SAM polyclonal antibody (1∶400, Abcam, Burlington, MA，USA） , basement membrane was stained by rabbit type Ⅳ Collagen polyclonal antibody (1∶2000, Millipore, Burlington, MA, US). After routine immunohistochemistry staining, the sections were observed under an optical microscope and images were taken. The images were analyzed by Image-Pro Plus 6.0（Media Cyberneties Image Technology Co., Austin, TX, USA） . The microvessel density (MVD) of the tumor was measured using methods described previously. 34 Primarily, MVD was calculated by counting the number of CD31-positive-stained vessels in the image X400. The positive area of α-SAM and the CD31-positive vessels on the same area were calculated according to a magnification of × 400. Then, the ratio of α-SAM/ CD31 was calculated. The method for calculating the ratio of Collagen Ⅳ/CD31 was same as above. In addition, under the microscope with 10-20X high-powered (200X), 5 sections of each sample in 5 random sights were observed.
Immunofluorescence (IF) of hypoxic tissue
The condition of tumor-bearing mice and grouping was as mentioned above in IHC. Then, a Hypoxyprobe TM -1 Kit (Hypoxyprobe, Inc., Burlington, MA, USA, containing of 100 mg solid pimonidazole HCI and 1.0 mL mouse IgG1 monoclonal antibody (Mab1) against protein adducts of pimonidazole formed when the tissue pO2 was below 10 mm Hg) was applied in the tumor hypoxia examination. 35 In brief, tumor-bearing mice were given pimonidazole (60 mg/kg, dissolved to 15 mg/mL in 0.9% saline) intraperitioneally 20 min before sacrifice. Then, tumor tissue was excised from mice and immediately frozen in liquid nitrogen and stored at -70 ℃ . For immunofluorescence, frozen tumors were cut into 10 µm thick sections with frozen section machine, six sections per tumor with 3 tumors in each group. The primary antibody to pimonidazole (1∶100) and the routinely stained with immunofluorescence was used. The sections were observed under a fluorescence microscope and the images were analyzed by Image-Pro Plus 6.0. Five randomly selected regions per slide were observed. The tumor tissue hypoxic area (%) was defined as the pimonidazole-positive area under a magnification of × 200.
Tumor vascular permeability
To further study the effect of Tan ⅡA on tumor vascular, another set of tumor-bearing mice was used. Four animals in each group were studied for vascular permeability using an Evans blue dye method. 36 In brief, 200 µL 2% Evans blue dye solution (20 mg/kg dissolved in saline, Sigma-Aldrich, Shanghai, China) was injected into the tail vein after the drugs of each group being continuously administrated for 14 d. The Evans blue in the vascular was washed by 15 mL saline through the lavage of heart after the dye circulated for 20 min. Thereafter, the mice were sacrificed and the tumor tissues were excised. The tissues were cut into small pieces and weighed, and the small pieces were extracted in 1 mL of formamide for 72 h. Level of the dye was detected by a spectrophotometer at a wavelength of 610 nm.
Distribution of Pegylated Liposomal Doxorubicin (PLD) in tumor
Tumor-bearing mice were divided randomly into three groups with 8 mice in each group, and received 0.2 mL Tan Ⅱ A (5 mg/kg), BV (5 mg/kg) and NS when the mean tumor diameter was 8 to 10 mm. PLD (8 mg/kg) was injected into the tail vein after the other drugs of each group being continuously administrated for 6 d. Animals were killed and tumors excised at 24 h following injection of PLD. Tumor tissues were embedded immediately in OCT compound, frozen in liquid nitrogen, and stored at -80 ℃ for tissue sectioning and immunofluorescence staining. Three cryostat sections with 10 µm thicknesses were cut from each tumor, mounted on glass slides, and allowed to air-dry. PLD auto-fluorescence was detected using Nikon Eclipse CI inverted fluorescence microscopy 475 to 485 nm excitation and 575 to 585 nm emission filters, and images of section were captured with a Nikon DS-U3 camera. Blood vascular in the tissue section were recognised by the expression of CD31 on endothelial cells. Following PLD imaging, tissue section was stained with a rat anti-mouse CD31 monoclonal antibody (1∶100, BD Biosciences, San Diego, CA, USA) for 1 h in 4 ℃ and then stained with goat anti-rat IgG (1∶ 400, Jackson ImmunoResearch Laboratories, Inc., Philadelphia, PA, USA) secondary antibody. Finally, sections were cover-slipped with a mounting medium containing anti-fluorescein quencher. Anti-CD31 fluorescence representing endothelial cells was visualized using 510 to 560 nm excitation and 590 nm emission filters. Composite images of PLD and CD31 were generated using Image Pro Plus (version 6.0) software (Media Cyberneties Image Technology Co., Austin, TX, US). The process of synthesis must ensure that the image displaying anti-CD31 staining was overlaid with the corresponding field of view displaying PLD fluorescence image, and the procedure using the method introduced by Primeau et al. 37 Penetration of PLD was measured using the Matrix Laboratory software application. Briefly, the composite images of PLD and CD31 were separated firstly, certainly, those two images from the same field. Then, the segmented blood vessel image was masked, so that all the blood vessels can be identified and be converted to a black and white binary image. In this 8 bit image, white color with an intensity of 255 determined the blood vessel density and the remaining pixels in this image had an intensity of 0. Then the image was formed to a new image by using the function of distance filter. In this image, the gray value of each point represented the distance of the point to the nearest vessel. Similarly, the PLD image was also switched to the binary image in which each PLD positive spot represented as its center point. The distance of each PLD spot from the nearest blood vessel was calculated by using the minimum function of Matlab. Every slide was took three horizons after the areas of necrosis and staining artifact were excluded and the noise from tissue auto-fluorescence be minimized. Each picture captured from the corresponding horizons was working out an average as the PLD penetration distance of the field. The mean penetration distance of the nine fields from three slides was taken as the final PLD penetration distance for each animal.
Treatment protocol
Hepa1-6 Hepatoma xenograft model was again set up as described above. When tumor volume reached approximately 200 mm 3 , mice were randomly divided to six groups of five. Group 1 received normal saline (NS); group 2 received 5 mg/kg sulfotanshinone sodium injection intravenously daily for 14 d (TNA); group 3 received 5 mg/kg bevacizumab injection intravenously daily for 14 d (BV); group 4 received 8 mg/ kg pegylated liposomal doxorubicin injection intravenously only once on day 7 (PLD). On day seven after the administration of sulfotanshinone sodium injection and bevacizumab injection treatment, 8 mg/kg pegylated liposomal doxorubicin injection was combined intravenously only the day and these groups were defined as group 5 (combined 1), group 6 (combined 2), respectively. All animals were sacrificed on day 15 and tumor diameters were measured every other day using calipers. The tumor volume (V) was calculated by the formula: V = W 2 × Y / 2; where W and Y are the smaller and larger perpendicular diameters, respectively.
Statistical analysis
Data were presented as mean ± standard error of mean. All data were analysed with SPSS 13.0 (SPSS Inc., SPSS for Windows, Version 13.0. Chicago, IL, USA) and GraphPad Prism5. One-way analysis of variance was conducted to test the differences between groups. A P < 0.05 was the significant level.
RESULTS
Tumor MVD, pericyte coverage and contact of basement membrane in tumor vessels On day 14 after Tan Ⅱ A and BV administration, the MVD was reduced to 76.14% and 67.95% of NS group, respectively. There was significantly difference in the MVD between the Tan ⅡA and NS groups (Figure 1A, 1B) . MVD of the BV group was less than that in the Tan ⅡA group, while there was no statistical significance between them (P > 0.05). The results showed that vessels in Tan Ⅱ A and BV group were more likely to cover by pericyte ( Figure  1C) . However, loss of pericyte was common in the vessels of the NS group ( Figure 1C) . Quantification of the α-SAM/CD31 ratio showed significantly more pericyte-covered vessels in the Tan Ⅱ A group than those in the NS group, while there was no significant differ- ence between Tan Ⅱ A group and BV group ( Figure  1D ). We also found that the basement membrane was thicker in NS group than in Tan Ⅱ A and BV group, especially in BV group ( Figure 1E ). There was a significant difference in the Collagen Ⅳ/CD31 ratio between the Tan ⅡA and NS group ( Figure 1F ) and this significant differences was also found between the Tan ⅡA and BV group ( Figure 1F ).
Hypoxic area
In Figure 2A , we found that the distributed of hypoxic areas mainly on the edge of necrosis tissues. The hypoxic areas in the Tan ⅡA group were at a low level compared to the control. However, from the figures, the hypoxic areas in the Tan Ⅱ A group was higher than in BV group, while the difference did not reach statistical significance (P > 0.05) ( Figure 2B ).
Tumor vessel leakiness
In the study, intratumoral vascular permeability were also evaluated after drug treatment. The results showed that Tan Ⅱ A and BV induced a significant reduction in tumor vessel permeability. On day 14 after the administration of Tan ⅡA and BV, Evans blue dye extravasation into the tissue of tumors decreased to 54.94% (20.39 ± 0.26 vs 37.12 ± 0.31, P < 0.01), 49.53% (18.39 ± 0.20 vs 37.12 ± 0.31, P < 0.01, respectively, while the dye level in Tan ⅡA group is higher than in the BV group.
Distribution of PLD
In Figure 3A , 3B, all of the images from three groups show that PLD distributed around tumor blood vessels and decreased with distance from the blood vessels (Figure 3C) . The fluorescence intensity of PLD is also decayed with distance from the blood vessels, so some regions of tumors had a detectable PLD. In addition, there were also some CD31-positive blood vessels without surrounding PLD. Table 1 and Figure 4 summarizes the PLD penetration distance in three groups. Tumor in the group Tan ⅡA and BV showed a significant increase in PLD penetration distance compared with the group NS (P = 0.037 and 0.011, respectively). The PLD penetration distance in Tan ⅡA group was lower than that in the BV group, however, there were no significant differences between them. The calculation of PLD-specific fluorescence spot among the three groups showed a trend of change similar to the trend seen in PLD penetration distance ( Table 1 ). The calculation of PLD fluorescence in Tan Ⅱ A and BV groups was significantly greater than that in the NS group (P = 0.036 and 0.021). Furthermore, no significant differences were found between group Tan ⅡA and BV in drug fluorescent count.
Anti-tumor efficacy of PLD
From the data above, we found that Tan ⅡA can normalize the structure and function of the tumor vasculature and improve the tumor microenvironment in a , respectively; P < 0.001]. Furthermore, either combined group 1 or combined group 2 had more effect on tumor inhibition compared with corresponding monotherapy with PLD group. The synergistic effect of combined group 1 was better than that in combined group 2, while the difference did not reach statistical significance (P > 0.05).
DISCUSSION
In this study, we established subcutaneous cancer models in C57/BL/6J mice by inoculation of mice hepatoma cell line Hepa1-6. The Administration of Tan Ⅱ A remodeled the structure and function of the tumor vasculature, and changed the anti-tumor efficacy of PLD through enhancing its penetration distance inside the tumor. In this study, we found that the contact of the basement membrane and endothelial cell was promoted and the tumor vessel leakiness were reduced in both the BV group and Tan Ⅱ A group, but BV group was significantly better than TanⅡA group in both of these measures.. Meanwhile, reduced MVD, increased coverage of pericyte, augmented PLD penetration distance inside tumor, and the therapeutic synergy when combined with PLD were found in both the BV group and TanⅡA group, but the differences were not statistically significant. So, the results indicated that Tan Ⅱ A promoted normalization of the tumor vasculature and function to some extent. In addition, TanⅡA can have a synergic action with PLD, and the effect was associated with augmented PLD penetration distance inside the tumor. In the previous study, Wang et al 38 found that TanⅡA did not inhibit MVD but improve microvessel integrity (MVI). Our study differs from their found in MVD. This difference may be attributed to the use of different animal model and observation times. Wang et al 38 established a double-tumor xenograft of hepatocellular carcinoma model and administration of Tan ⅡA after palliative resection, while we established subcutaneous cancer models in C57/BL/6J mice by inoculation of mice hepatoma cell line Hepa1-6 and administration of Tan Ⅱ A through intraperitoneal injection daily. Interestingly, we are identical in our views that Tan Ⅱ A could improve microvessel integrity. In addition, in our findings, Tan Ⅱ A could inhibit MVD, which is in agreement with the results of Xing et al. 22 Hypoxia is an important characteristic of the microenvironment of solid tumors. It is well known to aid tumor progression, metastasis and to increase the resistance to various treatments. 18 In our study, we found that TanⅡA decreases tumor hypoxia, which is consistent with the results of Wang et al, 38 in their study, a significantly alleviated residual tumor hypoxia was found after administration of Tan Ⅱ A. As the mechanisms of the decreased tumor hypoxia after Tan Ⅱ A therapy, some studies considered this is the consequences of a inhibited expression of HIF-1α. 39 However, another report believed that it resulting in a normalized vasculature. Our results confirm the view of latter. 18 The anti-angiogenic effect of TanⅡA has been verified by precious work. 22, 31 The dose of anti-angiogenic agents is important for anti-tumor activity. 19 Increase the dose of anti-angiogenic agents often results in excessive vascular regression, which may reduce the effect of anti-tumor activity because it compromises the delivery of drugs and oxygen. 25 Furthermore, increased doses of anti-angiogenic agents can have adverse effects on normal tissues. 25 Indeed, in the study to evaluate the ) was selected in this study. In our study, we found that the combination of TanⅡ A and PLD treatment led to even more pronounced synergistic anti-tumor activity. It was consistent with the results of Fu et al, 33 which found that Tan ⅡA ameliorates hypoxia-induced chemotherapy resistance to PLD in breast cancer cell lines, and the possible mechanism may be attributed to the down regulation of HIF-1α expression. However, there are certain weaknesses in our study. In order to verify whether Tan Ⅱ A could normalize the structure and function of the tumor vasculature, firstly, we did not explore the "time window" of Tan ⅡA. Besides, intersti-tial fluid pressure, which serves as useful indicators for tumor vessel function and tumor microenvironment, had not been evaluated due to equipment limitations in our laboratory. In conclusion, TanⅡA could normalize tumor vasculature in mice bearing hepatoma cell line Hepa1-6. Remodeling of the tumor vasculature resulted in reduced tumor vessel leakiness and improved the tumor microenvironment through reducing the tumor hypoxic. Meanwhile, those all resulted in improved delivery of PLD to the tumor and it is correlated closely with synergistic efficacy when Tan Ⅱ A combined with PLD. Take together, TanⅡA is under a huge potential in anti-tumor. In addition, the molecular mechanism underlying anti-tumor effect of Tan Ⅱ A also needs to be a further studied.
